

DRAFT - May 19, 2023
MEETING OF THE ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES (ACIP)
Centers for Disease Control and Prevention
Atlanta, Georgia 30329
June 21-23, 2023

Wednesday, June 21, 2023

8:00	Welcome & Introductions	Dr. Grace Lee (ACIP Chair) Dr. Melinda Wharton (ACIP Executive Secretary, CDC)
8:30	Respiratory Syncytial Virus Vaccines - Adult	
	Introduction	Dr. Camille Kotton (ACIP, WG Chair)
	Manufacturer presentation: Pfizer season 2 safety & efficacy; coadministration with influenza vaccine	TBD (Pfizer)
	Manufacturer presentation: GSK season 2 safety & efficacy; coadministration with influenza vaccine	TBD (GSK)
	Updated cost-effectiveness of the Pfizer and GSK vaccines (main CDC model)	Dr. David Hutton (University of Michigan)
	Comparison of cost effectiveness results of the main CDC model and each manufacturer model (Pfizer & GSK)	Dr. Ismael Ortega Sanchez (CDC/NCIRD)
	Updated Evidence to Recommendations (incl. GRADE) and clinical considerations for 2 vaccines (Pfizer & GSK)	Dr. Michael Melgar (CDC/NCIRD)
	Manufacturer presentation: Moderna RSV vaccine safety & efficacy in older adults	TBD (Moderna)
	Work group considerations on Moderna RSV vaccine	Dr. Amadea Britton (CDC/NCIRD)
11:30	Break	
11:45	Polio Vaccine	
	Introduction	Dr. Oliver Brooks (ACIP, WG Chair)
	Recommendations for Adult Polio Vaccination	Dr. Sarah Kidd (CDC/NCIRD)
1:15	Break	
2:00	Influenza Vaccine	
	Introduction	Dr. H. Keipp Talbot (ACIP, WG Chair)
	WG considerations and proposed recommendations	Dr. Lisa Grohskopf (CDC/NCIRD)
4:00	Break	
4:15	Public Comment	
4:35	<u>VOTES</u>	
	RSV Adult	
	Polio	
	Influenza	
5:30	Adjourn	

DRAFT - May 19, 2023
MEETING OF THE ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES (ACIP)
Centers for Disease Control and Prevention
Atlanta, Georgia 30329
June 21-23, 2023

Thursday, June 22, 2023

8:00	Welcome & Introductions	Dr. Grace Lee (ACIP Chair) Dr. Melinda Wharton (ACIP Executive Secretary, CDC)
8:35	Agency Updates <i>CDC, CMS, FDA, HRSA, IHS, OIDP, NIH</i>	
8:55	Pneumo Vaccines Introduction Economic analysis and public health impact of PCV20 use in children Comparison of cost-effectiveness analyses on PCV20 use in children Summary of WG interpretation on EtR and policy options	Dr. Kathy Poehling (ACIP, WG Chair) Dr. Charles Stoecker (Tulane University) Dr. Ayabina Diepreye (CDC/NCIRD) Dr. Miwako Kobayashi (CDC/NCIRD)
10:25	Break	
10:40	Dengue Vaccines Introduction Cost effectiveness analysis and health impacts of routine vaccination with TAK-003 dengue vaccine in Puerto Rico Cost effectiveness analysis for TAK-003 – CDC model and comparison to manufacturer model Partial EtR (including GRADE) for TAK-003 – problem, benefits and harms, resource use	Dr. Wilbur Chen (ACIP, WG Chair) Guido Espana Kaul Rajreni (CDC/NCIRD) Dr. Laura E Adams (CDC/NCEZID)
11:40	Break	
12:25	Chikungunya Vaccine Introduction Chikungunya vaccine among U.S. travelers and healthcare Chikungunya virus infection among laboratory workers Update on large chikungunya outbreak in Paraguay Workgroup considerations	Dr. Beth Bell (ACIP, WG Chair) Ms. Nicole Lindsey (CDC/NCEZID) Dr. Susan Hills (CDC/NCEZID) Dr. Susan Hills (CDC/NCEZID) Dr. Susan Hills (CDC/NCEZID)
1:25	Break	
1:40	Respiratory Syncytial Virus Vaccines - Pediatric/Maternal Introduction CDC model cost-effectiveness of Pfizer maternal RSVpreF Comparison of manufacturer and CDC cost-effectiveness models of Pfizer maternal RSVpreF vaccine Pfizer maternal RSVpreF vaccine evidence to recommendations (EtR), and clinical considerations Comparison of cost-effectiveness analyses for nirsevimab and Pfizer maternal RSVpreF vaccine Combined clinical considerations for use of nirsevimab and Pfizer maternal RSVpreF vaccine	Dr. Sarah Long (ACIP, WG Chair) Dr. David Hutton (University of Michigan) Dr. Ismael Ortega Sanchez (CDC/NCIRD) Dr. Katherine Fleming-Dutra (CDC/NCIRD) Dr. David Hutton (University of Michigan) Dr. Jefferson Jones (CDC, NCIRD)
4:40	Break	
4:50	Public Comment	
5:10	<u>VOTES</u>	
5:30	Pneumococcal Adjourn	Dr. Jeanne Santoli (CDC/NCIRD)

DRAFT - May 19, 2023
MEETING OF THE ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES (ACIP)
Centers for Disease Control and Prevention
Atlanta, Georgia 30329
June 21-23, 2023

Friday, June 23, 2023

8:00	Welcome & Introductions	Dr. Grace Lee (ACIP Chair)
8:10	Mpox Vaccine	
	Introduction	Dr. Pablo Sanchez (ACIP, WG Chair)
	Epidemiology update	Dr. Faisal Minhaj (CDC/NCEZID)
	Vaccine effectiveness update	Dr. Ian Kracalik (CDC/NCEZID)
	Clinical considerations for use of JYNNEOS during mpox	Dr. Agam Rao (CDC/NCEZID)
10:10	Break	
10:20	Meningococcal Vaccines	
	Introduction	Dr. Kathy Poehling (ACIP, WG Chair)
	Cost effectiveness analysis	Dr. Ismael Ortega-Sanchez (CDC/NCIRD)
	GRADE/EtR	Dr. Sam Crowe (CDC/NCIRD)
	Summary and workgroup considerations	Dr. Sam Crowe (CDC/NCIRD)
11:35	Break	
11:45	Vaccine Safety	TBD
12:30	Break	
12:40	COVID-19 Vaccines	
	Introduction	Dr. Matthew Daley (ACIP WG Chair)
	COVID-19 epidemiologic data for populations of focus	TBD
	Infection-induced and hybrid immunity	Dr. Jefferson Jones (CDC/NCIRD)
	COVID-19 vaccine effectiveness updates	Dr. Ruth Link-Gelles (CDC/NCIRD)
	Summary and Work Group Considerations	TBD
2:40	Adjourn	

Acronyms

CDC	Centers for Disease Control and Prevention
CMS	Centers for Medicare and Medicaid Services
COVID-19	Coronavirus disease 2019
EtR	Evidence to Recommendations Framework
FDA	Food and Drug Administration
GRADE	Grading of Recommendations Assessment, Development and Evaluation
HRSA	Health Resources and Services Administration
IHS	Indian Health Service
NCHHSTP	National Center for HIV, Hepatitis, STD and TB Prevention [of CDC/OID]
NCIRD	National Center for Immunization & Respiratory Diseases [of CDC/OID]
NCEZID	National Center for Emerging and Zoonotic Diseases [of CDC/OID]
NIAID	National Institute of Allergy and Infectious Diseases
OIDP	Office of Infectious Disease and HIV/AIDS Policy
SARS-CoV-2	Severe Acute Respiratory Syndrome Coronavirus 2
WG	Work Group
WHO	World Health Organization
VE	Vaccine Effectiveness